Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 20 2020 - 4:05PM
Business Wire
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology
company focused on innovative aesthetic and therapeutic offerings,
including its investigational neuromodulator product,
DaxibotulinumtoxinA for Injection, today announced new hire grants
totaling an aggregate of 40,500 inducement restricted stock awards
(“RSAs”) to nine employees. The RSAs vest over four years, with 25%
of the underlying shares vesting on each of the four anniversaries
of the applicable vesting commencement date, subject to the new
employee's continued service relationship with Revance through the
applicable vesting dates.
The Compensation Committee of Revance’s Board of Directors
approved the awards as an inducement material to the new employees’
employment in accordance with NASDAQ Listing Rule 5635(c)(4).
About Revance Therapeutics, Inc.
Revance Therapeutics, Inc. is a biotechnology company focused on
innovative aesthetic and therapeutic offerings, including its
next-generation neuromodulator product, DaxibotulinumtoxinA for
Injection. DaxibotulinumtoxinA for Injection combines a proprietary
stabilizing peptide excipient with a highly purified botulinum
toxin that does not contain human or animal-based components.
Revance has successfully completed a Phase 3 program for
DaxibotulinumtoxinA for Injection in glabellar (frown) lines and is
pursuing U.S. regulatory approval in 2020. Revance is also
evaluating DaxibotulinumtoxinA for Injection in the full upper
face, including glabellar lines, forehead lines and crow’s feet, as
well as in two therapeutic indications - cervical dystonia and
adult upper limb spasticity. To accompany DaxibotulinumtoxinA for
Injection, Revance owns a unique portfolio of premium products and
services for U.S. aesthetics practices, including the exclusive
U.S. distribution rights to the RHA® Collection of dermal fillers,
the first and only range of FDA-approved fillers for correction of
dynamic facial wrinkles and folds, and the HintMD fintech platform,
which includes integrated smart payment, subscription and loyalty
digital services. Revance has also partnered with Viatris to
develop a biosimilar to BOTOX®, which would compete in the existing
short-acting neuromodulator marketplace. Revance is dedicated to
making a difference by transforming patient experiences. For more
information or to join our team visit us at www.revance.com.
“Revance Therapeutics” and the Revance logo are registered
trademarks of Revance Therapeutics, Inc. RHA resilient hyaluronic
acid® and RHA® are trademarks of TEOXANE SA. BOTOX® is a registered
trademark of Allergan, Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201120005222/en/
Investors Revance Therapeutics, Inc.: Jeanie Herbert,
714-325-3584 jherbert@revance.com or Gilmartin Group, LLC.:
Laurence Watts, 619-916-7620 laurence@gilmartinir.com
Media Revance Therapeutics, Inc.: Sara Fahy, 949-887-4476
sfahy@revance.com or General Media: Y&R: Jenifer Slaw,
347-971-0906 jenifer.slaw@YR.com or Trade Media: Nadine Tosk,
504-453-8344 nadinepr@gmail.com
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Apr 2023 to Apr 2024